Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Zacks Research to Strong Sell

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Wall Street Zen cut Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, May 6th. Finally, Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, April 24th. Four research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Sell” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.5%

NYSE FMS opened at $21.67 on Wednesday. The business has a fifty day moving average price of $22.31 and a two-hundred day moving average price of $22.97. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $29.07. The stock has a market capitalization of $12.10 billion, a PE ratio of 11.40, a PEG ratio of 3.89 and a beta of 0.81.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The firm had revenue of $5.34 billion during the quarter. Equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.24 earnings per share for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. AQR Capital Management LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 14.2% in the first quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock valued at $356,000 after purchasing an additional 1,777 shares during the period. JPMorgan Chase & Co. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 160.3% in the second quarter. JPMorgan Chase & Co. now owns 37,610 shares of the company’s stock valued at $1,075,000 after purchasing an additional 23,163 shares during the period. American Century Companies Inc. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 21.3% in the second quarter. American Century Companies Inc. now owns 29,173 shares of the company’s stock valued at $833,000 after purchasing an additional 5,127 shares during the period. Russell Investments Group Ltd. increased its holdings in Fresenius Medical Care AG & Co. KGaA by 21.3% in the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after purchasing an additional 896 shares during the period. Finally, EverSource Wealth Advisors LLC increased its holdings in Fresenius Medical Care AG & Co. KGaA by 141.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock valued at $83,000 after purchasing an additional 1,704 shares during the period. 8.37% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high?flux dialyzers and bloodlines.